Eric Berthelet, MD FRCPC

Clinical Associate Professor
University of British Columbia (UBC)

Director of Head and Neck Cancer Radiation Oncology
Radiation Oncology Vancouver Cancer Centre (BCCA)*

Active Staff: British Columbia Cancer Agency (BCCA) – Vancouver Centre*
Associate Staff Vancouver General Hospital (VCH)

City: Vancouver
Hospital Authority: Provincial Health Services

Address: BCCA-VCC
600 West 10th Avenue
Vancouver, BC V5Z 4E6

Phone: 604.877.6000     Fax: 604.877.0505

Major Clinical Focus – Head & Neck Cancers & Lung Cancer

Special Interests

  • Radiation Oncology and Developmental Radiotherapeutics
  • Therapy for Prostate Cancer


  • International Baccalaureate (Sciences), Lester B Pearson College, Canada, 1985
  • Doctor of Medicine, University of Montreal, Canada, 1990
  • Radiation Oncology Residency training program, McGill University, Canada, 1996


  • Rotating Internship, Montreal general hospital, McGill University, Montreal, Quebec, Canada, 1990-1991
  • Licentiate of The Medical Council of Canada, Canada, 1992
  • Assistant Chief Resident (Radiation Oncology), McGill University, Montreal, Quebec, Canada, 1993-1994
  • Chief Resident (Radiation Oncology), McGill University, Montreal, Quebec, Canada, 1994
  • Fellow of the Royal College of Physicians & Surgeons of Canada (Radiation oncology), Royal College of Physicians & Surgeons of Canada, Canada, 1996
  • Diplomate, American board of Radiology, 1999

Biographic Summary ( Background, Academic Interests and Activities, Clinical Activities )

  • Clinical Director – Vancouver Rapid Access (VARA) Clinic for Palliative Radiation Treatment
  • Head & Neck Radiation Oncology Clinical Site Director
  • Chairman Radiation Oncology Head & Neck QA Rounds

1. Pai HH, Pickles T, Keyes M, Jones S, McDonald RE, Lesperance M, Berthelet E. Randomized study evaluating testosterone recovery using short-versus long-acting leuthenizing hormone releasing hormone agonists. Canadian Urological Association Journal 2011;5(3): 173-179.

2. Morris WJ, Keyes M, Palma D, Spadinger I, McKenzie MR, Agranovich A, Pickles T, Liu M, Kwan W, Wu J, Berthelet E, Pai. Population-based study of biochemical and survival outcomes after permanent 125 Iodine Brachytherapy for low- and intermediate-risk prostate cancer. Urology 2009;73(4):860-5.

3. Morris WJ, Keyes M, Palma D, McKenzie M, Spadinger I, Agranovich A, Pickles T, Liu M, Kwan W, Wu J, Lapointe V, Berthelet E, Pai H, Harrison R, Kwa W, Bucci J, Racz V, Woods R. Evaluation of dosimetric parameters and disease response after 125 iodine transperineal brachytherapy for low- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2009;73(5):1432-8.

4. Johnston H, Hilts M, Beckham W, Berthelet E. 3D ultrasound for prostate localization in radiation therapy: a comparison with implanted fiducial markers. Med Phys 2008;35(6):2403-13.

5. Germain F, Wai ES, Berthelet E, Truong PT, Lesperance M. Brain metastasis is an early manifestation of distant failure in stage III nonsmall cell lung cancer patients treated with radical chemoradiation therapy. Am J Clin Oncol. 2008; 31(6):561-6.

6. Petersen RP, Truong PT, Kader HA, Berthelet E, Lee JC, Hilts M, Kader AS, Beckham W, Olivotto IA. Target volume delineation for partial breast radiotherapy: clinical characteristics associated with low interobserver concordance. Int J Radiat Oncol Biol Phys 2007; 69(1):41-8.

7. Kader AS, Lim JT, Berthelet E, Petersen R, Ludgate D, Truong PT. Prognostic significance of blood transfusions in patients with esophageal cancer treated with combined chemo-radiotherapy. Am J Clin Oncol 2007; 30(5):492-7.

8. Berthelet E, Pickles T, Truong PT, Liu M, Pai HH, Kwan Wb, Lim JT; Members of the Prostate Cancer Outcomes Initiative. What is the optimal duration of androgen deprivation therapy in prostate cancer patients presenting with prostate-specific antigen levels > 20 ng/ml? Prostate Cancer Outcomes Initiative. Can J Urol. 2007; 14(4):3621-7.

* The British Columbia Cancer Agency (BCCA)-Vancouver Centre (VC) is the largest academic cancer centre for the BCCA, located in downtown Vancouver and treating about one third of the radiation oncology cancer patients in the Province of BC. Over 4360 cancer patients are seen each year in the radiation oncology department. There are 20 Radiation Oncology (RO) physician faculty with full disease site specialization and clinical programs of excellence, 2 General Practice (Internist) Oncology Physicians, 3 Clinical Fellows and 10 RO residents. The BCCA-Vancouver Centre also has 17 physicists and a graduate training program in physics, 15 nurses, >60 radiation therapists clerks, secretaries and many others within radiation oncology. General capabilities include 9 Linacs (including Truebeam), 1 cobalt, VMAT (first developed in the BCCA-VC), IMRT, SBRT, IGRT, HDR and LDR brachytherapy suites, and Protons (at the TRIUMF centre). The Vancouver Centre radiation oncology department conducts all levels of research (basic, translational, clinical, population), and is the main educational institution in BC for the training of graduate (residents) and undergraduate (medical) students. The interdisciplinary Radiation Oncology team is part of the even larger multidisciplinary and provincial teams.